Structural Genomics Consortium

Structural Genomics Consortium
Name	Structural Genomics Consortium
Founded	0 2004
Type	Public–private partnership
Focus	Structural biology, Drug discovery
Headquarters	University of Toronto, Canada
Key people	Aled Edwards (Founding CEO)
Website	www.thesgc.org

Structural Genomics Consortium. The Structural Genomics Consortium is a global public–private partnership that operates as a not-for-profit organization dedicated to accelerating drug discovery through open-access structural biology research. Founded in 2004, it focuses on determining the three-dimensional structures of human and pathogen proteins, with a particular emphasis on challenging and medically relevant targets. Its work is predicated on a pre-competitive model, making all research outputs—including protein structures, chemical probes, and data—immediately available to the global scientific community without restriction.

History and mission

The consortium was established in 2004 through initial funding from Wellcome Trust, GlaxoSmithKline, and Genome Canada, with foundational leadership from scientist Aled Edwards. Its creation was a direct response to perceived bottlenecks in biomedical research, where protein structural information was often proprietary, slow to generate, or focused only on well-understood targets. The mission from its inception has been to operate in the pre-competitive space, reducing the risk and cost of early-stage drug discovery for both academia and the pharmaceutical industry by generating foundational knowledge and tools. This model was inspired by earlier large-scale public science projects like the Human Genome Project, applying similar principles of open data to structural genomics.

Research focus and approach

The primary research focus is the experimental determination of three-dimensional structures of proteins, particularly those from the human proteome and proteins from pathogens like Mycobacterium tuberculosis and Plasmodium falciparum. A major emphasis is placed on understudied protein families, such as kinases, epigenetic regulators, and G protein-coupled receptor domains, which are high-value targets for therapeutic intervention. The approach integrates high-throughput X-ray crystallography, supported by complementary techniques like cryo-electron microscopy and mass spectrometry. Beyond structures, the research pipeline includes the development and characterization of high-quality chemical probes—selective small-molecule inhibitors or activators—to functionally annotate proteins and validate them as drug targets.

Key achievements and impact

By the early 2020s, the consortium had deposited over 2,000 unique protein structures into the public Protein Data Bank, significantly expanding the structural coverage of the human proteome. Its development and dissemination of over 150 chemical probes for targets like bromodomains and histone methyltransferases have become critical tools for thousands of research laboratories worldwide, catalyzing new fields of study. These open-source tools have directly contributed to the identification of novel therapeutic targets and have seeded numerous drug discovery programs in both industry and academia. The impact is evidenced by a high citation rate for its data sets and a proven track record of de-risking early-stage research for entities like Merck & Co. and Pfizer.

Organizational structure and funding

The organization operates as a distributed entity with major laboratory hubs at the University of Toronto in Canada, the University of Oxford in the United Kingdom, and the Karolinska Institutet in Sweden, with additional affiliated sites. It is governed by a board comprising representatives from its funders and academic partners. Core funding is provided through a unique membership model where pharmaceutical companies, government agencies, and charitable foundations contribute as equal partners. Major funders have historically included Wellcome Trust, Innovate UK, the Swedish Foundation for Strategic Research, and companies such as Janssen Pharmaceutica and Novartis. This multi-stakeholder funding ensures research agendas address broad, pre-competitive scientific challenges.

Collaborations and partnerships

Collaboration is central to its model, involving deep partnerships with hundreds of academic groups globally and ongoing alliances with major pharmaceutical industry partners. It maintains formal collaborations with institutions like the European Molecular Biology Laboratory and the Broad Institute for specific technology or disease-area projects. The consortium also partners with patient advocacy groups and non-profits, such as the Michael J. Fox Foundation, to steer research toward areas of high unmet medical need, including Parkinson's disease and cancer. These partnerships often extend beyond data generation to include joint development of new research methodologies and open-source informatics platforms.

Open science policy and data sharing

The consortium is a leading proponent of open science in biomedical research, enforcing a strict policy that mandates immediate public release of all research outputs, including structural coordinates, assay data, and chemical compound structures, with no patent filings. This policy is legally binding for all scientists and funders within the partnership. All data are deposited in major public repositories like the Protein Data Bank, ChEMBL, and PubChem at the time of publication. This radical openness is designed to prevent duplication of effort, accelerate validation of findings, and ensure that the entire scientific community can build upon its research without delay or legal barriers, fostering a more efficient and collaborative ecosystem for discovery.

Category:Biomedical research organizations Category:Structural biology Category:Open science